Abstract

Obesity-driven type 2 diabetes (T2D) is increasingly recognized as a chronic disorder of “metabolic memory” 
(MM), in which prior exposure to obesogenic and hyperglycemic milieus leaves long-lasting molecular scars 
that sustain insulin resistance, β-cell dysfunction, and complications even after risk factors are controlled. 
Epigenetic mechanisms such as DNA methylation, histone modifications, chromatin remodeling, noncoding 
RNAs, and epitranscriptomic marks provide a plausible substrate for this persistence. Human and experimental 
data show that obesity and hyperglycemia reshape epigenetic landscapes in adipose tissue, liver, skeletal muscle, 
vascular endothelium, kidney, immune cells, and pancreatic islets, altering networks that regulate nutrient 
sensing, inflammation, oxidative stress, mitochondrial function, and cell survival. This review focuses on MM 
in obesity-driven diabetes rather than classical microvascular complication models. We summarize how 
obesogenic diets, lipotoxicity, and chronic low-grade inflammation generate epigenetic imprints that lock in 
pathogenic transcriptional programs across metabolic tissues. Particular attention is given to DNA methylation 
changes at adipokine, lipid handling, and insulin signaling genes; histone acetylation and methylation patterns 
that sustain inflammatory and oxidative pathways; and noncoding RNA networks that stabilize these 
phenotypes. We then review evidence for the reversibility of these imprints. Weight loss, dietary quality, 
physical activity, bariatric surgery, and antidiabetic drugs can partially remodel epigenetic marks, with tissue- 
and locus-specific differences in plasticity. Emerging data suggest that early-life and puberty represent critical 
windows during which epigenetic programming by obesogenic environments is particularly durable. Finally, 
we discuss pharmacological epigenetic modifiers, including histone deacetylase (HDAC) and DNA 
methyltransferase (DNMT) inhibitors, and small molecules targeting chromatin readers and writers, as 
potential tools to erase MM, balanced against safety and specificity concerns. Understanding MM in obesity
driven diabetes reframes prevention and treatment as a race between early, aggressive metabolic control and 
the establishment of hard-to-reverse epigenetic scars. Mapping which marks are stable, which are plastic, and 
which predict clinical outcomes will be central to developing biomarker-guided, epigenetically-informed 
therapies.